Background
Patients with platinum-resistant ovarian cancer have limited therapeutic options available to them. Treatment is largely comprised of chemotherapy, which is known to have limited efficacy where just 4% and 13% will benefit and substantial toxicity.
No biomarker-driven approaches have been indicated for this population.
Clinically meaningful antitumor activity and an acceptable safety profile were seen with the use of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer harboring high folate receptor–alpha (FRα) expression, according to the results of the phase 3 SORAYA trial (NCT04296890) presented during the The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.
About the Study in ovarian cancer
The global, single-arm, phase 3 SORAYA trial enrolled patients with platinum-resistant ovarian cancer who were treated with 1 to 3 prior regimens and experienced recurrence within 6 months after the last platinum dose they had received.
To be eligible for enrollment, patients needed to have high-grade serous histology and have received prior Avastin.
Patients needed to have tumors that demonstrated FRα-high with immunohistochemistry PS2+ scoring.
Study Results – Patients with Platinum-Resistant Ovarian Cancer Harboring High Folate Receptor–Alpha (FRα) Expression
This antibody-drug conjugate (ADC) elicited a response rate (percentage of patients whose tumors decreased) of 32.4% in the patient population (n = 105).
- Among the 34 responders, 5 patients achieved a complete remission
- 29 patients experienced a partial response (percentage of patients whose tumors decreased between 30-50%)
- 7% of patients achieved stable disease
- 0% experienced disease progression
- The median duration of response was 6.9 months with the drug
- Moreover, the median progression-free survival (The time it took until the disease progressed under the treatment) with Mirvetuximab Soravtansine was 4.3 months.
What is Mirvetuximab Soravtansine?
Mirvetuximab Soravtansine is an antibody-drug conjugate (ADC) comprised of an FRα-binding antibody, a cleavable linker, and maytansinoid DM4.
Findings from a pooled analysis of prior studies that examined the ADC in 70 patients with FRα-high, platinum-resistant ovarian cancer who previously received 1 to 3 therapies, which included Avastin showed:
- Response Rate of 31.4%
- Median Duration of Response of 7.8 months
- Median Time Until Disease Progression of 4.4 months
Side Effects
Most side effects were low-grade, reversible ocular and gastrointestinal events.
Serious treatment-related side effects were experienced by 8% of patients.
A total of 7 patients discontinued treatment with the ADC because of toxicity.
Takeaway Message for ovarian cancer patients
Phase 3 SOROYA trial revealed promising response rates with Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.
Talk to us so see if we can help you to actually get the most advanced treatments
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
Read more about Ovarian cancer>>
